Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy
| Autor: | J D, Bitran, B, Samuels, Y, Trujillo, L, Klein, L, Schroeder, J, Martinec |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Dose-Response Relationship Drug Receptor ErbB-2 Remission Induction Gene Expression Breast Neoplasms Genes erbB-2 Middle Aged Combined Modality Therapy Immunohistochemistry Disease-Free Survival Clinical Trials Phase II as Topic Chemotherapy Adjuvant Antineoplastic Combined Chemotherapy Protocols Humans Female Treatment Failure Neoplasm Recurrence Local Bone Marrow Transplantation Follow-Up Studies Neoplasm Staging |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research. 2(9) |
| ISSN: | 1078-0432 |
| Popis: | Twenty-five patients with high-risk stage II and IIIA breast cancer (10 or more involved lymph nodes) were treated with six cycles of standard-dose chemotherapy (5-fluorouracil, doxorubicin, and cyclophosphamide) followed by high-dose chemotherapy (2.5 g/m2 cyclophosphamide for 3 days and 225 mg/m2 thiotepa for 3 days) with autologous hematopoietic progenitor cell support. The actuarial relapse free survival at 3 years is 80%; the actuarial survival at 3 years is 96%. Four patients relapsed systemically between 6 and 18 months; all four patients who relapsed had breast cancers that overexpressed Her2/neu. In contrast, none of the 21 patients who had no or borderline overexpression of Her2/neu relapsed (P = 0.00004, Fisher's exact test). Patients with high-risk stage II and IIIA breast cancer who have overexpression of Her2/neu appear to be at a high risk for relapse, even when treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|